Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug cocktail takes on Hard-to-Treat cancers

NCT ID NCT07466160

First seen Mar 20, 2026 · Last updated Jun 23, 2026 · Updated 14 times

Summary

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how well the combination works. About 280 participants will take part, and the main focus is on safety and tumor control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Chest Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200043, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

7MW3711 and JS207 (two experimental drugs) given together, sometimes with chemotherapy (cisplatin or carboplatin)

What this could lead to

If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.

What could go wrong

This is an early-phase (1b/2) trial, so the main goals are safety and dosing—not yet proof of effectiveness. The drugs may cause side effects or fail to shrink tumors.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.